Philip Morris International Inc.: 10-K Risk Factor Changes

2025 vs 2024  ·  SEC EDGAR  ·  2026-07-05
Other years: 2026 vs 2025
✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

3
New Risks
3
Removed
7
Modified
23
Unchanged
🟢 New in Current Filing We may not successfully identify, complete, or realize the benefits from strategic acquisitions, divestitures, joint ventures, or investments. 🔒
🟢 New in Current Filing Our management uses certain key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions and such metrics may not accurately reflect all of the aspects of our business needed to make such evaluations and decisions, in particular as our business continues to evolve. 🔒
🟢 New in Current Filing The research, development, and commercialization of non-recreational cannabinoid products subjects the Company to legal, regulatory, reputational and other risks. 🔒
🔴 No Match in Current Filing PMI, Swedish Match and Vectura Fertin Pharma may be subject to uncertainties that could adversely affect our respective businesses, and adversely affect the financial results of our combined businesses. 🔒
🔴 No Match in Current Filing We may be unable to fully realize the expected benefits from the acquisitions of Swedish Match or Vectura Fertin Pharma. 🔒
🔴 No Match in Current Filing Swedish Match and Vectura Fertin Pharma may have liabilities that are not known to us. 🔒
🟡 Modified We may be unsuccessful in our efforts to differentiate smoke-free products and cigarettes with respect to taxation. 🔒
🟡 Modified Litigation related to tobacco products and nicotine products could substantially reduce our profitability and could severely impair our liquidity. 🔒
🟡 Modified Our revenues may be materially adversely affected as a result of counterfeiting, contraband, cross-border purchases, illicit products, non-tax-paid volume produced by local manufacturers and other non-compliant or illicit cigarettes or smoke-free products. 🔒
🟡 Modified We may be required to write down assets due to impairment, which could have a material adverse effect on our results of operations or financial position. 🔒
🟡 Modified The financial and business performance of our smoke-free products is less predictable than our cigarette business. 🔒
🟡 Modified Accounting adjustments related to acquisitions could adversely affect our financial results. 🔒
🟡 Modified We may be unsuccessful in our attempts to introduce, commercialize, and grow smoke-free products in existing and new markets, and regulators may prohibit or significantly restrict the commercialization of these products or the communication of scientifically substantiated information and claims. 🔒
13 changes in this historical filing

Historical year-over-year comparisons (2025 vs 2024 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →